Latest Price Forecast of Margetuximab in 2025
Margetuximab (margetuximab-cmkb) is an anti-HER2 monoclonal antibody, mainly suitable for adult patients with metastatic HER2-positive breast cancer combined with chemotherapy. These patients typically have disease progression despite receiving two or more anti-HER2 therapies, at least one of which is for metastatic disease. Margetuximab activates the immune system by specifically binding to the HER2 receptor, thereby achieving targeted attack on tumor cells and has good therapeutic potential.
At present, the original drug of margetuximab in China has been officially launched, but due to its short time on the market, the specific market price is not yet fully clear. In addition, this drug is not currently covered by medical insurance, so patients need to bear the corresponding costs when purchasing the drug. In terms of drug prices, patients need to consult relevant medical institutions or pharmacies to obtain the latest pricing and drug purchasing information.
In the international market, the original drug of margetuximab has been launched in many countries and regions. The common specification is 250mg/10ml*1 bottle/box, and its price is roughly more than 30,000 yuan. The specific price will be affected by exchange rate fluctuations and market factors. Due to the specificity of the drug and its indications for specific groups, its price is relatively high. In addition, there are currently no generic drugs of margituximab on the market, which means that patients mainly rely on the original drug when choosing treatment.
As research on the treatment ofHER2-positive breast cancer continues to deepen, margetuximab may play an increasingly important role in future clinical practice. It is expected that drug prices may be adjusted as market demand increases and treatment standards are constantly updated. Patients should fully communicate with their doctors when using this drug, develop a personalized treatment plan, and pay attention to the latest relevant research and market trends in order to make better decisions.
Reference materials:https://www.margenza.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)